Evren Alici

Artiklar

Article: NATURE BIOMEDICAL ENGINEERING. 2024;8(11):1453-1468
Antibody-displaying extracellular vesicles for targeted cancer therapy
Wiklander OPB; Mamand DR; Mohammad DK; Zheng W; Jawad Wiklander R; Sych T; Zickler AM; Liang X; Sharma H; Lavado A; Bost J; Roudi S; Corso G; Lennaard AJ; Abedi-Valugerdi M; Maeger I; Alici E; Sezgin E; Nordin JZ; Gupta D; Goergens A; EL Andaloussi S
Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2024;43(1):13
Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease
Neo SY; Oliveira MMS; Tong L; Chen Y; Chen Z; Cismas S; Burduli N; Malmerfelt A; Teo JKH; Lam K-P; Alici E; Girnita L; Wagner AK; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2023;12(1):2233402
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8⁺ T cells towards the center of human lung tumors
Brownlie D; von Kries A; Valenzano G; Wild N; Yilmaz E; Safholm J; Al-Ameri M; Alici E; Ljunggren H-G; Schliemann I; Aricak O; de Flon FH; Michaelsson J; Marquardt N
Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: NATURE COMMUNICATIONS. 2023;14(1):6035
Modulation of lytic molecules restrain serial killing in γδ T lymphocytes
Sandoz PA; Kuhnigk K; Szabo EK; Thunberg S; Erikson E; Sandstroem N; Verron Q; Brech A; Watzl C; Wagner AK; Alici E; Malmberg K-J; Uhlin M; Oenfelt B
Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Journal article: CYTOTHERAPY. 2023;25(6):s13-s14
13 Tissue Engineering: GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hållstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: SCIENCE SIGNALING. 2023;16(780):eabq0752
SHP-1 localization to the activating immune synapse promotes NK cell tolerance in MHC class I deficiency
Schmied L; Luu TT; Sondergaard JN; Hald SH; Meinke S; Mohammad DK; Singh SB; Mayer C; Casoni GP; Chrobok M; Schlums H; Rota G; Truong HM; Westerberg LS; Guarda G; Alici E; Wagner AK; Kadri N; Bryceson YT; Saeed MB; Hoglund P
Article: BIOMOLECULAR INTERACTIONS, PT A. 2023;178:43-61
A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids.
Schwietzer YA; Susek KH; Chen Z; Alici E; Wagner AK
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(11):e005577
Adaptive single-KIR⁺NKG2C⁺ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikstroem K; Blomberg P; Alici E; Felices M; oenfelt B; Hoeglund P; Valamehr B; Ljunggren H-G; Bjoerklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg K-J; Sohlberg EAlla författare
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(10):e005308
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
Neo SY; Jing X; Tong L; Tong D; Gao J; Chen Z; De Los Santos MC; Burduli N; Ferreira SDS; Wagner AK; Alici E; Rolny C; Cao Y; Lundqvist A
Article: CURRENT ISSUES IN MOLECULAR BIOLOGY. 2022;44(9):3859-3871
Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells
Rasul KH; Hussain A; Reilly H; Karvouni M; Dahlberg CIM; Al-Attar MS; Wagner AK; Alici E; Mohammad DK
Journal article: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022;22:s41-s41a
P-010: Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Journal article: HEMASPHERE. 2022;6(Suppl):1318-1319
P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB‐BASED ANTI‐ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
Meinke S; Kadri N; Bi S; Bostancioglu B; Markey C; Breitmeyer JB; Hussain A; Krishnan R; Kaufmann GF; Alici E
Journal article: HEMASPHERE. 2022;6(Suppl ):1326-1327
P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
Lund J; Nahi H; Meinke S; Holmqvist P-H; Ljunggren H-G; Aschan J; Alici E
Article: CELL REPORTS MEDICINE. 2022;3(2):100508
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist P-H; Walther-Jallow L; Mellstrom K; Liwing J; Gustafsson C; Mansson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren H-G; Alici E
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-GAlla författare
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Afram G; Susek KH; Uttervall K; Wersall JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: LIFE SCIENCE ALLIANCE. 2021;4(4):e202000723
Short-term IL-15 priming leaves a long-lasting signalling imprint in mouse NK cells independently of a metabolic switch
Luu TT; Schmied L; Nguyen N-A; Wiel C; Meinke S; Mohammad DK; Bergo M; Alici E; Kadri N; Ganesan S; Hoglund P
Article: EMBO REPORTS. 2021;22(3):e51329
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25⁺/CD54⁺ NK cells
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(1):23-30
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2021;9:612714
The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function
Abomaray F; Wagner AK; Chrobok M; Ekblad-Nordberg A; Gidlof S; Alici E; Gotherstrom C
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(6):751-754
Outcome of COVID-19 in multiple myeloma patients in relation to treatment
Susek KH; Gran C; Ljunggren H-G; Alici E; Nahi H
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(10):5508-5522
Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(2):196-202
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment
Afram G; Gran C; Borg Bruchfeld J; Wagner AK; Hussain A; Alici E; Nahi H
Article: STEM CELL REPORTS. 2020;14(4):648-662
Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II
Petrus-Reurer S; Winblad N; Kumar P; Gorchs L; Chrobok M; KathleenWagner A; Bartuma H; Lardner E; Aronsson M; Reyes AP; Andre H; Alici E; Kaipe H; Kvanta A; Lanner F
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(4_Supplement):a55
Abstract A55: Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+ sarcomas and other malignancies
Sayitoglu EC; Chrobok M; Georgoudaki A-M; Josey BJ; Hartman M; Vallabhaneni E; Herekar R; Bergeron S; Krueger R; Sutlu T; Alici E; Temple HT; Duru AD
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(4_Supplement):a21
Abstract A21: Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer
Parlar A; Sayitoglu EC; Pamukcu C; Georgoudaki A-M; Ozkazanc D; Aras M; Josey B; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Sutlu T; Duru AD
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:40
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
Sayitoglu EC; Georgoudaki A-M; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(6):588-596
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Bruchfeld JB; Wallblom A; Alici E; Gahrton G; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Uttervall K; Bruchfeld JB; Gran C; Walinder G; Mansson R; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2019;49(8):1278-1290
Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki A-M; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Article: CYTOTHERAPY. 2019;21(3):315-326
Characterization of human natural killer cells for therapeutic use mas
Wagner AK; Alici E; Lowdell MW
Article: CANCERS. 2019;11(1):E69-69
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Chrobok M; Dahlberg CIM; Sayitoglu EC; Beljanski V; Nahi H; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Article: PLOS ONE. 2019;14(2):e0211927
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi H; Chrobok M; Gran C; Lund J; Gruber A; Gahrton G; Ljungman P; Wagner AK; Alici E
Article: CANCER MEDICINE. 2018;7(6):2256-2268
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frolund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist U-H; Nahi H
Journal article: JOURNAL OF IMMUNOLOGY. 2018;200(Supplement_1):169.19
Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells
Sayitoglu EC; Ozkazanc D; Sarac A; Parlar A; Alici E; Erman B; Duru AD; Sutlu T
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;100(4):386-388
Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients
Gran C; Gahrton G; Alici E; Nahi H
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018;81(1):183-193
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Article: BLOOD ADVANCES. 2017;1(10):619-623
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson B-M; Wihlborg A-K; Ali M; Lemonakis K; Johnsson E; Niroula A; Cibulskis C; Weinhold N; Foersti A; Alici E; Langer C; Pfreundschuh M; Goldschmidt H; Mellqvist U-H; Turesson I; Waage A; Hemminki K; Golub T; Nahi H; Gullberg U; Hansson M; Nilsson B
Article: HUMAN GENE THERAPY METHODS. 2017;28(2):78-90
Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration
Bandeira VS; Tomas HA; Alici E; Carrondo MJT; Coroadinha AS
Article: MOLECULAR NEUROBIOLOGY. 2017;54(2):874-887
Perforin Promotes Amyloid Beta Internalisation in Neurons
Lana E; Khanbolouki M; Degavre C; Samuelsson E-B; Akesson E; Winblad B; Alici E; Lithner CU; Behbahani H
Article: SCIENTIFIC REPORTS. 2016;6:37996
Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+dendritic cells
Thuy TL; Ganesan S; Wagner AK; Sarhan D; Meinke S; Garbi N; Haemmerling G; Alici E; Karre K; Chambers BJ; Hoglund P; Kadri N
Article: STEM CELL REPORTS. 2016;6(4):607-617
Wnt/β-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells
Mansson-Broberg A; Rodin S; Bulatovic I; Ibarra C; Lofling M; Genead R; Wardell E; Felldin U; Granath C; Alici E; Le Blanc K; Smith CIE; Salasova A; Westgren M; Sundstrom E; Uhlen P; Arenas E; Sylven C; Tryggvason K; Corbascio M; Simonson OE; Osterholm C; Grinnemo K-H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(1):46-54
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Nahi H; Vatsveen TK; Lund J; Heeg BMS; Preiss B; Alici E; Moller MB; Wader KF; Moller HEH; Groseth LA; Ostergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Article: PLOS ONE. 2015;10(9):e0138248
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: HUMAN IMMUNOLOGY. 2014;75(8):777-784
Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia
da Silva RF; Petta CA; Derchain SF; Alici E; Guimaraes F
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Kviele HH; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Nasman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: STEM CELL RESEARCH & THERAPY. 2014;5(1):9
Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data
Martins JP; Santos JM; de Almeida JM; Filipe MA; Teixeira de Almeida MV; Paiva Almeida SC; Agua-Doce A; Varela A; Gilljam M; Stellan B; Pohl S; Dittmar K; Lindenmaier W; Alici E; Graca L; Cruz PE; Cruz HJ; Barcia RN
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: PLOS ONE. 2014;9(9):e107712
Characterization of Stem-Like Cells in Mucoepidermoid Tracheal Paediatric Tumor
Lim ML; Ooi BNS; Jungebluth P; Sjoqvist S; Hultman I; Lemon G; Gustafsson Y; Asmundsson J; Baiguera S; Douagi I; Gilevich I; Popova A; Haag JC; Rodriguez AB; Lim J; Lieden A; Nordenskjold M; Alici E; Baker D; Unger C; Luedde T; Vassiliev I; Inzunza J; Ahrlund-Richter L; Macchiarini P
Article: PLOS ONE. 2014;9(7):e101819
The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: HUMAN GENE THERAPY. 2012;23(10):1090-1100
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Article: CURRENT OPINION IN MOLECULAR THERAPEUTICS. 2010;12(6):724-733
IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers
Alici E
Article: CYTOTHERAPY. 2010;12(8):1044-1055
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Article: LEUKEMIA RESEARCH. 2010;34(12):1627-1629
Constitutional inv(3) in myelodysplastic syndromes
Gahrton C; Nahi H; Jansson M; Wallblom A; Alici E; Sutlu T; Samuelsson J; Gahrton G
Article: HUMAN GENE THERAPY. 2010;21(8):929-941
TK.007: A Novel, Codon-Optimized HSVtk(A168H) Mutant for Suicide Gene Therapy
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Felldin U; Alici E; Gahrton G; von Laer D; Dilber MS; Fehse B
Article: IMMUNOTHERAPY. 2009;1(5):753-764
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Bjorkstrom NK; Soderdahl G; Cederlund K; Kimby E; Aschan J; Ringden O; Ljunggren H-G; Dilber MS
Article: ONCOLOGY REPORTS. 2009;22(1):137-142
Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation
Paul E; Sutlu T; Deneberg S; Alici E; Bjorkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Article: METHODS IN MOLECULAR BIOLOGY. 2009;506:127-137
Retroviral gene transfer into primary human natural killer cells.
Alici E; Sutlu T; Sirac Dilber M
Journal article: BLOOD. 2008;112(11):5153
The Prognostic Significance of 8p21 Deletion in Multiple Myeloma
Nahi H; Sutlu T; Alici E; Gahrton G
Journal article: BLOOD. 2008;112(11):5148
Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation
Paul E; Sutlu T; Alici E; Gahrton G; Nahi H
Article: BLOOD. 2008;111(6):3155-3162
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici E; Sutlu T; Boejrkstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(12):1839-1846
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren H-G; Dilber MS
Article: CANCER GENE THERAPY. 2007;14(3):227-232
Long-term follow-up of gene-marked CD34⁺ cells after autologous stem cell transplantation for multiple myeloma
Alici E; Bjorkstrand B; Treschow A; Aints A; Smith CIE; Gahrton G; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(11):1320-1328
Efficient gene transfer into primary human natural killer cells by retroviral transduction
Guven H; Konstantinidis KV; Alici E; Aints A; Abedi-Valugerdi M; Christensson B; Ljunggren HG; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(2):159-164
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
Konstantinidis KV; Alici E; Aints A; Christensson B; Ljunggren HG; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2004;32(11):1064-1072
Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: Establishment of a new syngeneic murine model of multiple myeloma
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Journal article: ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY. 2001;121(1-2):65-66
Effect of preoperative chemotherapy on the outcome of surgical treatment of vertebral tuberculosis:: retrospective analysis of 434 cases
Alici E; Akçali Ö; Tatari H; Günal I
Journal article: SPINE. 1996;21(17):1991-1995
Detection of Mycobacterium tuberculosis in formaldehyde solution-fixed, paraffin-embedded tissue by polymerase chain reaction in Pott's disease
Berk RH; Yazici M; Atabey N; Ozdamar OS; Pabuccuoglu U; Alici E
Visa fler

Alla övriga publikationer

Meeting abstract: BLOOD. 2023;142:1960
A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk
Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Conference publication: 2023;:a1174
1067 A three stage immune targeted immuno-cytokine platform that delivers inflammatory signals to the tumor microenvironment
Rabinovich B; Zhou X; Takimoto J; Khanna N; Yoon S; Alici E
Letter: CANCER COMMUNICATIONS. 2023;43(7):855-859
Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1
Tong L; Kremer V; Neo SY; Liu Y; Chen Y; Wagner AK; Yang Y; Chen Z; Seitz C; Tobin NP; Ligtenberg MA; Alici E; Chen X; Haglund F; Seliger B; Harmenberg U; Colon E; Plogell A-HS; Liu LL; Lundqvist A
Preprint: RESEARCH SQUARE. 2023
Modulation of lytic molecules restrain serial killing in γδ T lymphocytes
Onfelt B; Sandoz P; Kuhnigk K; Szabo E; Thunberg S; Erikson E; Sandström N; Verron Q; Brech A; Watzl C; Wagner A; Alici E; Malmberg K-J; Uhlin M
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Conference publication: CYTOTHERAPY. 2023;25(6):S13-S14
GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hallstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Conference publication: BLOOD. 2022;140:12440-12441
HSV1716 Infects Multiple Myeloma Cells and Leads to CD138 Downregulation
Susek KH; Flore VN; Karvouni M; Meinke S; Conner J; Powers C; Allen R; Wagner AK; Alici E
Conference publication: 2022;:a1110
1068 A ROR1 specific CD3 bispecific T-cell engager engineered for solid tumors with an expanded therapeutic window
Rabinovich B; Zhou X; Takimoto J; Song P; Alici E; Khanna N
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022;22:S46-S47
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Preprint: BIORXIV. 2022
Control of NK cell tolerance in MHC class I-deficiency by regulated SHP-1 localization to the activating immune synapse
Schmied L; Luu T; Søndergaard J; Meinke S; Mohammad D; Singh S; Mayer C; Casoni G; Chrobok M; Schlums H; Rota G; Truong H; Westerberg L; Guarda G; Alici E; Wagner A; Kadri N; Bryceson Y; Saeed M; Höglund P
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022;22:S46-S47
PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Review: FRONTIERS IN IMMUNOLOGY. 2022;13:825979
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
Karvouni M; Vidal-Manrique M; Lundqvist A; Alici E
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022;22:S41
Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Meeting abstract: BLOOD. 2021;138:4796
CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
Nahi H; Chrobook M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Walther-Jallow L; Liwing J; Klimkowska M; Gahrton G; Ljungman P; Ljunggren H-G; Alici E
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Editorial comment: CLINICAL CHEMISTRY. 2021;67(10):1309-1311
Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma
Kashif M; Alici E; Nahi H
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(3):E63-E65
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2021;94(6)
SHP-1 expression and localization are associated with functional education of murine natural killer cells
Luu T; Schmied L; Sondergaard JN; Saeed MB; Meinke S; Mohammad D; Casoni GP; Schlums H; Truong HM; Westerberg L; Bryceson Y; Alici E; Wagner AK; Kadri N; Hoglund P
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(4):49-50
Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Pamukcu C; Georgoudaki A-M; Ozkazanc D; Aras M; Josey B; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Sutlu T; Duru AD
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(4):64-65
Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+sarcomas and other malignancies.
Sayitoglu EC; Chrobok M; Georgoudaki A-M; Josey BJ; Hartman M; Vallabhaneni E; Herekar R; Bergeron S; Krueger R; Sutlu T; Alici E; Temple HT; Duru AD
Conference publication: BLOOD. 2019;134:1848
Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
Karvouni M; Zhou H; Kathleen A; Ma Q; Baloch AH; Zhu T; Zhang H; Gilljam M; Lundqvist A; Kaufmann GF; Alici E
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E169
Combination of herpes-simplex based oncolytic viruses (HSV-OV) with natural killer (NK) cells in Multiple Myeloma
Susek KH; Meinke S; Wagner AK; Ljunggren H-G; Alici E
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E163-E164
A novel antiCD38-CAR construct increases the in vitro responsiveness of NK cells against Multiple Myeloma cells
Karvouni M; Wagner AK; Baloch AH; Gilljam M; Lundqvist A; Alici E
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E170
Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model
Wagner AK; Baloch AH; Chrobok M; Dahlberg C; Gahrton G; Nahi H; Ljunggren H-G; Alici E
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E158
Reinstating anti-tumor activity of Natural Killer cells
Caliskan C; Chrobok M; Wagner AK; Bruchfeld JB; Nahi H; Alici E
Preprint: SSRN ELECTRONIC JOURNAL. 2019
A Brief IL-15 Pulse Results in JAK3-Dependent Phosphorylation of ITAM-Associated Signaling Molecules and a Long-Lasting Priming Imprint in Mouse NK Cells
Luu TT; Nguyen N-A; Ganesan S; Meinke S; Kadri N; Alici E; Höglund P
Meeting abstract: BLOOD. 2018;132:195
Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS
Sohlberg E; Haroun-Izquierdo A; Bjorklund AT; Cooley S; Wiiger MT; Goodridge P; Hoel HJ; Pfefferle A; Chrobook M; Kremer V; Hellstrom-Lindberg E; Ask EH; Pontus B; Valamehr B; Guldevall K; van Ooijen H; Onfelt B; Alici E; Ljunggren H-G; Miller JS; Malmberg K-J
Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2018;59(9)
In vitro and in vivo immunologic characterization of human embryonic stem cell-derived retinal pigment epithelial cells
Petrus-Reurer S; Gorchs L; Chrobok M; Wagner AK; Lardner E; Bartuma H; Aronsson M; Westman S; Alici E; Kaipe H; Lanner F; Kvanta AP
Conference publication: JOURNAL OF IMMUNOLOGY. 2018;200(1)
Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells
Sayitoglu EC; Ozkazanc D; Sarac A; Parlar A; Alici E; Erman B; Duru AD; Sutlu T
Conference publication: EUROPEAN JOURNAL OF HUMAN GENETICS. 2018;26:558
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson B; Wihlborg A; Ali M; Lemonakis K; Johnsson E; Niroula A; Cibulskis C; Weinhold N; Foersti A; Alici E; Langer C; Pfreundschuh M; Goldschmidt H; Mellqvist U; Turesson I; Waage A; Hemminki K; Golub T; Nahi H; Gullberg U; Hansson M; Nilsson B
Review: FRONTIERS IN IMMUNOLOGY. 2018;9:2159
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
Susek KH; Karvouni M; Alici E; Lundqvist A
Meeting abstract: CANCER RESEARCH. 2017;77:5030
The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Nahi H; Lotfi K
Conference publication: HUMAN GENE THERAPY. 2017;28(12):A31-A32
Engineering antigen-specific NK cells via TCR gene transfer: A novel source for adoptive immunotherapy
Parlar A; Pamukcu C; Ozkazanc D; Aras M; Dahlberg C; Chrobok M; Zahedimaram P; Ikromzoda L; Sayitoglu EC; Alici E; Erman B; Duru AD; Sutlu T
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):295
Reactive oxygen species are linked with general phosphorylation status and functional education of natural killer cells
Thuy TL; Vignesh S; Wagner AK; Chrobok M; Schlums H; Tornmalm J; Kadri N; Meinke S; Widengren J; Bryceson Y; Alici E; Johannsson S; Hoglund P
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):295
Interleukin-15 primes natural killer cell functions through proximal crosstalk with activating receptors
Thuy TL; Ngoc AN; Ganesan S; Meinke S; Wagner AK; Chrobok M; Alici E; Hoglund P
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):348
Optimized genetic modification of primary human NK cells
Wagner AK; Chrobok M; Hussain A; Gilljam M; Dahlberg CIM; Sutlu T; Duru AD; Nahi H; Lundqvist A; Ljunggren H-G; Alici E
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):342
Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu
Chrobok M; Dahlberg CIM; Sayitoglu C; Nahi H; Sarhan D; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(3):473-477
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
Review: ONCOIMMUNOLOGY. 2016;5(4):e1115178
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Koehl U; Kalberer C; Spanholtz J; Lee DA; Miller JS; Cooley S; Lowdell M; Uharek L; Klingemann H; Curti A; Leung W; Alici E
Conference publication: BLOOD. 2015;126(23):5366
Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach
Lund J; Alici E; Chrobok M; Gruber A; Ahmadi T; Khan I; Nahi H
Conference publication: BLOOD. 2015;126(23):3047
The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex
Lund J; Karstorp S; Alici E; Gruber A; Lauri B; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Conny C; Waage A; Gimsing P; Vangsted AJ; Frolund UC; Hardling M; Mellqvist U-H; Nahi H
Review: FRONTIERS IN IMMUNOLOGY. 2015;6:605
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
Dahlberg CIM; Sarhan D; Chrobok M; Duru AD; Alici E
Conference publication: HUMAN GENE THERAPY. 2015;26(10):A6
Innate immune sensors restrict lentiviral gene delivery to human natural killer cells: novel perspectives on the use of viral vectors
Sayitoglu EC; Duru AD; Chrobok M; Chiang C; Parlar A; Senturk GH; Erman B; Alici E; Sutlu T
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S17
Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Letter: MEDICAL ONCOLOGY. 2013;30(2):569
In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al
Sutlu T; Alici E; Gahrton G; Nahi H
Conference publication: HUMAN GENE THERAPY. 2013;24(12):A97-A98
Comparison of different strategies for the establishment of retroviral cell lines: random vs. targeted integration
Bandeira VS; Tomas H; Alici E; Alves PM; Carrondo M; Coroadinha AS
Conference publication: HAEMATOLOGICA. 2013;98:326
MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS
Lund J; Uttervall K; Liwing J; Aschan J; Alici E; Holmberg E; Nahi H
Conference publication: HAEMATOLOGICA. 2013;98:326-327
CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS
Uttervall K; Lund J; Liwing J; Holmberg E; Alici E; Aschan J; Nahi H
Book chapter: THE CLINIBOOK. 2012;p. 187-193
A4-2 Ex-vivo expansion of human mesenchymal stem cells
Cruz PE; Cruz HJS; Bárcia RN; Santos JM; Pohl S; Gilljam M; Dittmar KEJ; Lindenmaier W; Alici E
Book chapter: THE CLINIBOOK. 2012;p. 201-207
A4-4 Genetically modified NK cells for cancer treatment: facts and visions
Alici E; Gahrton G
Conference publication: HAEMATOLOGICA. 2012;97:610
BORTEZOMIB, RESPONSE AND RETREATMENT IN 1ST, 2ND, 3RD AND 4TH LINE OF TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA
Andreasson A; Uttervall K; Liwing J; Alici E; Nasman P; Aschan J; Nahi H
Conference publication: HUMAN GENE THERAPY. 2012;23(10):A151
Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Letter: CYTOTHERAPY. 2011;13(6):767-768
Ex vivo expansion of natural killer cells: a question of function
Sutlu T; Alici E
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(2):137-147
Clinical impact of chromosomal aberrations in multiple myeloma
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
Review: CURRENT GENE THERAPY. 2010;10(6):508-515
GMP Facilities for Manufacturing of Advanced Therapy Medicinal Products for Clinical Trials: An Overview for Clinical Researchers
Alici E; Blomberg P
Review: IMMUNOTHERAPY. 2010;2(4):521-537
Suicide gene therapy for graft-versus-host disease
Georgoudaki A-M; Sutlu T; Alici E
Conference publication: HUMAN GENE THERAPY. 2010;21(10):1416
Expansion of NK cells for cancer immunotherapy: from process optimization to clinical evaluation
Sutlu T; Gahrton G; Alici E
Conference publication: BONE MARROW TRANSPLANTATION. 2010;45:S301
Superior performance of the novel suicide gene TK.007 in adoptive immunotherapy models both in vitro and in vivo
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Otte J; Felldin U; Alici E; von Laer D; Dilber S; Fehse B
Review: JOURNAL OF INTERNAL MEDICINE. 2009;266(2):154-181
Natural killer cell-based immunotherapy in cancer: current insights and future prospects
Sutlu T; Alici E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(2):266-268
The prognostic significance of 8p21 deletion in multiple myeloma
Sutlu T; Alici E; Jansson M; Wallblom A; Dilber MS; Gahrton G; Nahi H
Conference publication: HUMAN GENE THERAPY. 2009;20(11):1464
The novel HSVtk mutant TK.007 shows superior performance both in vitro and in vivo
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Otte J; Felldin U; Alici E; von Laer D; Dilber S; Fehse B
Conference publication: MOLECULAR THERAPY. 2009;17:S223
A Novel, Codon-Optimised HSVtk(A168H) Mutant for Suicide Gene Therapy
Preuss E; Treschow A; Otte J; Bruecher D; Felldin U; Alici E; Dilber S; Fehse B
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(10):1541-1552
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg K-J; Bryceson YT; Carlsten M; Andersson S; Bjorklund A; Bjorkstrom NK; Baumann BC; Fauriat C; Alici E; Dilber MS; Ljunggren H-G
Conference publication: HUMAN GENE THERAPY. 2008;19(10):1183
Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma
Alici E; Sutlu T; Bjokstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Conference publication: HUMAN GENE THERAPY. 2008;19(10):1141
Optimal ouaselect and thymidine kinase functionality in T cells is defined by the transgene cassette
Treschow A; Schambach A; Felldin U; Alici E; Gahrton G; Fehse B; Baum C; Dilber MS
Conference publication: HUMAN GENE THERAPY. 2007;18(10):992-993
Natural killer cells kill syngeneic myeloma cells in C57Bl/KaLwRij upon adoptive transfer
Alici E; Sutlu T; Gahrton G; Dilber S
Doctoral thesis: 2006
Therapeutic potential of natural killer cells in multiple myeloma
Alici E
Visa fler

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI